Brasil - português - CPVS (Compêndio de Produtos Veterinários)

laboratÓrio bio-vet ltda - vac. encefalomielite; - vacinas, corantes e diluentes (biolÓgicos)

Brasil - português - CPVS (Compêndio de Produtos Veterinários)

ceva veterinÁria ltda - vac. influenza equina (ver gripe equina); vac. tÉtano; vac. encefalomielite; - vacinas, corantes e diluentes (biolÓgicos)

Brasil - português - CPVS (Compêndio de Produtos Veterinários)

ceva saÚde animal ltda - vac. bouba aviÁria; vac. encefalomielite; vac. micoplasmose; - vacinas, corantes e diluentes (biolÓgicos)

Brasil - português - CPVS (Compêndio de Produtos Veterinários)

ceva saÚde animal ltda - vac. bouba aviÁria; vac. contra laringotraqueÍte das aves; vac. encefalomielite; - vacinas, corantes e diluentes (biolÓgicos)

União Europeia - português - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinúria, paroxística - imunossupressores seletivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

União Europeia - português - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunossupressores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

União Europeia - português - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunossupressores - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

msd animal health, lda. - vacina contra o vírus da encefalomielite aviária e varíola - liofilizado e solvente para suspensão - vacinas virais vivas - aves de exploração

União Europeia - português - EMA (European Medicines Agency)

merck sharp & dohme b.v. - rotavírus sorotipo g1, sorotipo g2, sorotipo g3, sorotipo g4, sorotipo p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq é indicado para a imunização ativa de lactentes de seis semanas a 32 semanas para prevenção de gastroenterite por infecção por rotavírus. rotateq é para ser usada com base em recomendações oficiais.

União Europeia - português - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibacterianos para uso sistémico, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 e 5. deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes antibacterianos..